BioSpace News Archive

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the U.S. Food and Drug Administration (FDA) approved both VOQUEZNA™ TRIPLE PAK™ (vonoprazan tablets.

Bioventus Inc., a global leader in innovations for active healing, announced that its subsidiary, Bioventus LLC, has withdrawn its offering of senior notes that was announced on Tuesday, April 26, 2022.

CANbridge Pharmaceuticals Inc. announced that data from its gene therapy research agreement with the Horae Gene Therapy Center, at the UMass Chan Medical School, will be presented at the ASGCT 25th Annual Meeting, being held in Washington D.C.

Coherus BioSciences, Inc., announced that effective April 27, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 240,000 shares of the common stock of the Company to 13 newly hired employees with a per share exercise price of $9.28, the closing trading price on the grant date.

AMPEL BioSolutions announces a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat inflammatory skin diseases, such as Lupus, Psoriasis, Atopic Dermatitis and Scleroderma.

CenExel announces the acquisition of iResearch (“CenExel iResearch”), a leading multi-specialty research site business with locations in Decatur, GA and Savannah, GA. .

Cardiawave SA, a deeptech medical device manufacturer that has developed VALVOSOFT® a revolutionary non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults, today announced the authorization by the French National Agency for the Safety of Medicines and Health Products to proceed with a new clinical study in France.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2022 on May 10 at 4:30 p.m. ET / 1:30 p.m. PT.

The global animal healthcare market size is expected to be worth around US$ 76.82 billion by 2030 from valued at US$ 53.15 billion in 2021, growing at a CAGR of 4.2% from 2022 to 2030.

The global artificial intelligence in healthcare market is surging, with an overall revenue growth expectation of hundreds of billions of dollars within the next eight years.